Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2023

Open Access 01-12-2023 | Diabetes | Review

Diabetes- versus smoking-related thrombo-inflammation in peripheral artery disease

Authors: T. Alnima, R. I. Meijer, H. M.H. Spronk, M. Warlé, H. ten Cate

Published in: Cardiovascular Diabetology | Issue 1/2023

Login to get access

Abstract

Peripheral artery disease (PAD) is a major health problem with increased cardiovascular mortality, morbidity and disabling critical limb threatening ischemia (CLTI) and amputation. Diabetes mellitus (DM) and cigarette smoke are the main risk factors for the development of PAD. Although diabetes related PAD shows an accelerated course with worse outcome regarding complications, mortality and amputations compared with non-diabetic patients, current medical treatment does not make this distinction and includes standard antiplatelet and lipid lowering drugs for all patients with PAD. In this review we discuss the pathophysiologic mechanisms of PAD, with focus on differences in thrombo-inflammatory processes between diabetes-related and smoking-related PAD, and hypothesize on possible mechanisms for the progressive course of PAD in DM. Furthermore, we comment on current medical treatment and speculate on alternative medical drug options for patients with PAD and DM.
Literature
1.
2.
Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–e30.PubMedCrossRef
3.
Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24(8):1433–7.PubMedCrossRef
4.
American Diabetes A. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26(12):3333–41.CrossRef
5.
Stoberock K, Kaschwich M, Nicolay SS, Mahmoud N, Heidemann F, Riess HC, et al. The interrelationship between diabetes mellitus and peripheral arterial disease. Vasa. 2021;50(5):323–30.PubMedCrossRef
6.
Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921–9.PubMedCrossRef
7.
Aboyans V, Desormais I, Lacroix P, Salazar J, Criqui MH, Laskar M. The general prognosis of patients with peripheral arterial disease differs according to the disease localization. J Am Coll Cardiol. 2010;55(9):898–903.PubMedCrossRef
8.
Haltmayer M, Mueller T, Horvath W, Luft C, Poelz W, Haidinger D. Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease. Int Angiol. 2001;20(3):200–7.PubMed
9.
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28(3):354–62.PubMedCrossRef
10.
11.
Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364(18):1746–60.PubMedCrossRef
12.
Joosten MM, Pai JK, Bertoia ML, Rimm EB, Spiegelman D, Mittleman MA, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA. 2012;308(16):1660–7.PubMedPubMedCentralCrossRef
13.
van Haelst ST, Haitjema S, de Vries JP, Moll FL, Pasterkamp G, den Ruijter HM, et al. Patients with diabetes differ in atherosclerotic plaque characteristics and have worse clinical outcome after iliofemoral endarterectomy compared with patients without diabetes. J Vasc Surg. 2017;65(2):414–21. e5.PubMedCrossRef
14.
Korosoglou G, Giusca S, Langhoff R, Lichtenberg M, Lawall H, Schellong S, et al. Safety and Effectiveness of Endovascular Therapy for the treatment of Peripheral Artery Disease in patients with and without diabetes Mellitus. Angiology. 2022;73(10):956–66.PubMedCrossRef
15.
Lee MS, Choi BG, Rha SW. Impact of diabetes mellitus on 5-year clinical outcomes following successful endovascular revascularization for peripheral artery disease. Vasc Med. 2020;25(1):33–40.PubMedCrossRef
16.
Prefontaine D, Morin A, Jumarie C, Porter A. In vitro bioactivity of combustion products from 12 tobacco constituents. Food Chem Toxicol. 2006;44(5):724–38.PubMedCrossRef
17.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.PubMedCrossRef
18.
19.
Kamceva G, Arsova-Sarafinovska Z, Ruskovska T, Zdravkovska M, Kamceva-Panova L, Stikova E. Cigarette smoking and oxidative stress in patients with coronary artery disease. Open Access Maced J Med Sci. 2016;4(4):636–40.PubMedPubMedCentralCrossRef
20.
Kullo IJ, Rooke TW. CLINICAL PRACTICE. Peripheral artery disease. N Engl J Med. 2016;374(9):861–71.PubMedCrossRef
21.
Abbas AE, Zacharias SK, Goldstein JA, Hanson ID, Safian RD. Invasive characterization of atherosclerotic plaque in patients with peripheral arterial disease using near-infrared spectroscopy intravascular ultrasound. Catheter Cardiovasc Interv. 2017;90(3):461–70.PubMedCrossRef
22.
Creager MA, Kaufman JA, Conte MS. Clinical practice. Acute limb ischemia. N Engl J Med. 2012;366(23):2198–206.PubMedCrossRef
23.
Soor GS, Vukin I, Leong SW, Oreopoulos G, Butany J. Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases. Pathology. 2008;40(4):385–91.PubMedCrossRef
24.
Narula N, Dannenberg AJ, Olin JW, Bhatt DL, Johnson KW, Nadkarni G, et al. Pathology of Peripheral Artery Disease in patients with critical limb ischemia. J Am Coll Cardiol. 2018;72(18):2152–63.PubMedCrossRef
25.
Kumagai S, Amano T, Takashima H, Waseda K, Kurita A, Ando H, et al. Impact of cigarette smoking on coronary plaque composition. Coron Artery Dis. 2015;26(1):60–5.PubMedCrossRef
26.
Mayhan WG, Sharpe GM. Effect of cigarette smoke extract on arteriolar dilatation in vivo. J Appl Physiol. 1996;81(5):1996–2003.PubMedCrossRef
27.
Mayhan WG, Sharpe GM. Chronic exposure to nicotine alters endothelium-dependent arteriolar dilatation: effect of superoxide dismutase. J Appl Physiol. 1999;86(4):1126–34.PubMedCrossRef
28.
Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509–15.PubMedCrossRef
29.
Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg. 2003;25(1):16–22.PubMedCrossRef
30.
Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8):1476–85.PubMedCrossRef
31.
Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999;33(3):634–9.PubMedCrossRef
32.
Smith T, Dhunnoo G, Mohan I, Charlton-Menys V. A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease. Platelets. 2007;18(4):245–8.PubMedCrossRef
33.
Baidildinova G, Nagy M, Jurk K, Wild PS, van der Ten Cate H. Soluble platelet release factors as biomarkers for Cardiovascular Disease. Front Cardiovasc Med. 2021;8:684920.PubMedPubMedCentralCrossRef
34.
Fusegawa Y, Goto S, Handa S, Kawada T, Ando Y. Platelet spontaneous aggregation in platelet-rich plasma is increased in habitual smokers. Thromb Res. 1999;93(6):271–8.PubMedCrossRef
35.
Liu Z, Xiang Q, Mu G, Xie Q, Zhou S, Wang Z, et al. The effect of smoking on residual platelet reactivity to clopidogrel: a systematic review and meta-analysis. Platelets. 2020;31(1):3–14.PubMedCrossRef
36.
Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D, et al. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv. 2012;5(3):293–300.PubMedCrossRef
37.
Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes. 1998;47(6):945–52.PubMedCrossRef
38.
Akai T, Naka K, Okuda K, Takemura T, Fujii S. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metab Res. 1983;15(11):523–6.PubMedCrossRef
39.
Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest. 2004;34(3):205–9.PubMedCrossRef
40.
Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia. 2001;44(2):188–95.PubMedCrossRef
41.
Kessler L, Wiesel ML, Attali P, Mossard JM, Cazenave JP, Pinget M. Von Willebrand factor in diabetic angiopathy. Diabetes Metab. 1998;24(4):327–36.PubMed
42.
Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep. 2007;7(3):223–7.PubMedCrossRef
43.
Trovati M, Anfossi G, Cavalot F, Massucco P, Mularoni E, Emanuelli G. Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. Diabetes. 1988;37(6):780–6.PubMedCrossRef
44.
Westerbacka J, Yki-Jarvinen H, Turpeinen A, Rissanen A, Vehkavaara S, Syrjala M, et al. Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol. 2002;22(1):167–72.PubMedCrossRef
45.
Schaeffer G, Wascher TC, Kostner GM, Graier WF. Alterations in platelet Ca2 + signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia. 1999;42(2):167–76.PubMedCrossRef
46.
Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol. 2002;89(9):1117–9.PubMedCrossRef
47.
Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731–7.PubMedCrossRef
48.
Giunzioni I, Bonomo A, Bishop E, Castiglioni S, Corsini A, Bellosta S. Cigarette smoke condensate affects monocyte interaction with endothelium. Atherosclerosis. 2014;234(2):383–90.PubMedCrossRef
49.
Doring Y, Soehnlein O, Weber C. Neutrophil Extracellular Traps in atherosclerosis and atherothrombosis. Circ Res. 2017;120(4):736–43.PubMedCrossRef
50.
Zhang H, Qiu SL, Tang QY, Zhou X, Zhang JQ, He ZY, et al. Erythromycin suppresses neutrophil extracellular traps in smoking-related chronic pulmonary inflammation. Cell Death Dis. 2019;10(9):678.PubMedPubMedCentralCrossRef
51.
Farkas AZ, Farkas VJ, Gubucz I, Szabo L, Balint K, Tenekedjiev K, et al. Neutrophil extracellular traps in thrombi retrieved during interventional treatment of ischemic arterial diseases. Thromb Res. 2019;175:46–52.PubMedCrossRef
52.
Chatzigeorgiou A, Mitroulis I, Chrysanthopoulou A, Legaki AI, Ritis K, Tentolouris N, et al. Increased neutrophil extracellular traps related to smoking intensity and subclinical atherosclerosis in patients with type 2 diabetes. Thromb Haemost. 2020;120(11):1587–9.PubMedCrossRef
53.
Kremers BMM, Birocchi S, van Oerle R, Zeerleder S, Spronk HMH, Mees BME, et al. Searching for a common thrombo-inflammatory basis in patients with deep vein thrombosis or peripheral artery disease. Front Cardiovasc Med. 2019;6:33.PubMedPubMedCentralCrossRef
54.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.PubMedCrossRef
55.
Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286–92.PubMedCrossRef
56.
Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based european prospective investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812–7.PubMedCrossRef
57.
Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011;118(7):1952–61.PubMedPubMedCentralCrossRef
58.
Menegazzo L, Ciciliot S, Poncina N, Mazzucato M, Persano M, Bonora B, et al. NETosis is induced by high glucose and associated with type 2 diabetes. Acta Diabetol. 2015;52(3):497–503.PubMedCrossRef
59.
Fadini GP, Menegazzo L, Rigato M, Scattolini V, Poncina N, Bruttocao A, et al. NETosis delays Diabetic Wound Healing in mice and humans. Diabetes. 2016;65(4):1061–71.PubMedCrossRef
60.
Bryk AH, Prior SM, Plens K, Konieczynska M, Hohendorff J, Malecki MT, et al. Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis. Cardiovasc Diabetol. 2019;18(1):49.PubMedPubMedCentralCrossRef
61.
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–808.PubMedPubMedCentralCrossRef
62.
63.
Carter AM. Complement activation: an emerging player in the pathogenesis of cardiovascular disease. Scientifica (Cairo). 2012;2012:402783.PubMed
64.
Hertle E, Stehouwer CD, van Greevenbroek MM. The complement system in human cardiometabolic disease. Mol Immunol. 2014;61(2):135–48.PubMedCrossRef
65.
Li M, Yu D, Williams KJ, Liu ML. Tobacco smoke induces the generation of procoagulant microvesicles from human monocytes/macrophages. Arterioscler Thromb Vasc Biol. 2010;30(9):1818–24.PubMedPubMedCentralCrossRef
66.
Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arterioscler Thromb Vasc Biol. 2013;33(7):1460–7.PubMedCrossRef
67.
Barua RS, Ambrose JA, Srivastava S, DeVoe MC, Eales-Reynolds LJ. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation. 2003;107(18):2342–7.PubMedCrossRef
68.
Undas A, Ariens RA. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011;31(12):e88–99.PubMedCrossRef
69.
Ariens RA, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and hypertension. Arterioscler Thromb Vasc Biol. 1999;19(8):2012–6.PubMedCrossRef
70.
Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006;55(1):202–8.PubMedCrossRef
71.
Aoki I, Shimoyama K, Aoki N, Homori M, Yanagisawa A, Nakahara K, et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol. 1996;27(3):560–6.PubMedCrossRef
72.
Soma P, Swanepoel AC, Bester J, Pretorius E. Tissue factor levels in type 2 diabetes mellitus. Inflamm Res. 2017;66(5):365–8.PubMedCrossRef
73.
Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, et al. The role of Advanced Glycation End Products in Aging and metabolic Diseases: Bridging Association and Causality. Cell Metab. 2018;28(3):337–52.PubMedPubMedCentralCrossRef
74.
Calabro P, Cirillo P, Limongelli G, Maddaloni V, Riegler L, Palmieri R, et al. Tissue factor is induced by resistin in human coronary artery endothelial cells by the NF-kB-dependent pathway. J Vasc Res. 2011;48(1):59–66.PubMedCrossRef
75.
n der Toorn FA, de Mutsert R, Lijfering WM, Rosendaal FR, van Hylckama Vlieg A. Glucose metabolism affects coagulation factors: the NEO study. J Thromb Haemost. 2019;17(11):1886–97.PubMedCrossRef
76.
Abdul Razak MK, Sultan AA. The importance of measurement of plasma fibrinogen level among patients with type- 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(2):1151–8.PubMedCrossRef
77.
Pieters M, van Zyl DG, Rheeder P, Jerling JC, van der Loots du T, et al. Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thromb Res. 2007;120(3):439–46.PubMedCrossRef
78.
Ten Cate H, Hemker HC. Thrombin generation and atherothrombosis: what does the evidence indicate? J Am Heart Assoc. 2016;5(8).
79.
Kleinegris MF, Konings J, Daemen JW, Henskens Y, de Laat B, Spronk HMH, et al. Increased clot formation in the absence of increased thrombin generation in patients with peripheral arterial disease: a case-control study. Front Cardiovasc Med. 2017;4:23.PubMedPubMedCentralCrossRef
80.
Haidl H, Schlagenhauf A, Cimenti C, Schweintzger S, Grangl G, Leschnik B, et al. Regular smoking is not associated with increased thrombin generation in young adults. J Thromb Haemost. 2013;11(7):1433–5.PubMedCrossRef
81.
Beijers HJ, Ferreira I, Spronk HM, Bravenboer B, Dekker JM, Nijpels G, et al. Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation–the Hoorn Study. Thromb Res. 2012;129(5):557–62.PubMedCrossRef
82.
Barua RS, Sy F, Srikanth S, Huang G, Javed U, Buhari C, et al. Acute cigarette smoke exposure reduces clot lysis–association between altered fibrin architecture and the response to t-PA. Thromb Res. 2010;126(5):426–30.PubMedCrossRef
83.
Simpson AJ, Gray RS, Moore NR, Booth NA. The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol. 1997;97(1):208–13.PubMedCrossRef
84.
Newby DE, Wright RA, Labinjoh C, Ludlam CA, Fox KA, Boon NA, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation. 1999;99(11):1411–5.PubMedCrossRef
85.
Cefalu WT, Schneider DJ, Carlson HE, Migdal P, Gan Lim L, Izon MP, et al. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care. 2002;25(12):2123–8.PubMedCrossRef
86.
Konieczynska M, Fil K, Bazanek M, Undas A. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis. Thromb Haemost. 2014;111(4):685–93.PubMedCrossRef
87.
Pandolfi A, Iacoviello L, Capani F, Vitacolonna E, Donati MB, Consoli A. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia. 1996;39(12):1425–31.PubMedCrossRef
88.
Sogaard M, Nielsen PB, Skjoth F, Eldrup N, Larsen TB. Temporal changes in secondary Prevention and Cardiovascular Outcomes after revascularization for peripheral arterial disease in Denmark: a Nationwide Cohort Study. Circulation. 2021;143(9):907–20.PubMedCrossRef
89.
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.PubMedPubMedCentralCrossRef
90.
Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–8.PubMedCrossRef
91.
Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.CrossRef
92.
Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32(4):531–40.PubMedPubMedCentralCrossRef
93.
Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–39.CrossRef
94.
Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90(6):625–8.PubMedCrossRef
95.
Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, et al. Comparative efficacy and safety of different Antiplatelet Agents for Prevention of Major Cardiovascular events and Leg Amputations in patients with peripheral arterial disease: a systematic review and network Meta-analysis. PLoS ONE. 2015;10(8):e0135692.PubMedPubMedCentralCrossRef
96.
Rocca B, Patrono C. Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a new perspective. Diabetes Res Clin Pract. 2020;160:108008.PubMedCrossRef
97.
Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost. 2012;10(7):1220–30.PubMedCrossRef
98.
Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011;106(3):491–9.PubMedCrossRef
99.
Erlinge D, Varenhorst C, Braun OO, James S, Winters KJ, Jakubowski JA, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J Am Coll Cardiol. 2008;52(24):1968–77.PubMedCrossRef
100.
Cimmino G, Loffredo FS, De Rosa G, Cirillo P. Colchicine in Athero-Thrombosis: Molecular Mechanisms and clinical evidence. Int J Mol Sci. 2023;24(3).
101.
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the Prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62.PubMedCrossRef
102.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–47.PubMedCrossRef
103.
104.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMedCrossRef
105.
Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, et al. Anti-inflammatory therapy with Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018;71(21):2392–401.PubMedCrossRef
106.
Protogerou AD, Zampeli E, Fragiadaki K, Stamatelopoulos K, Papamichael C, Sfikakis PP. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis. 2011;219(2):734–6.PubMedCrossRef
107.
Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J. 2021;42(42):4389–400.PubMedPubMedCentralCrossRef
108.
Warnatsch A, Ioannou M, Wang Q, Papayannopoulos V. Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. Science. 2015;349(6245):316–20.PubMedPubMedCentralCrossRef
109.
Knight JS, Luo W, O’Dell AA, Yalavarthi S, Zhao W, Subramanian V, et al. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis. Circ Res. 2014;114(6):947–56.PubMedPubMedCentralCrossRef
110.
Bystrzycka W, Manda-Handzlik A, Sieczkowska S, Moskalik A, Demkow U, Ciepiela O. Azithromycin and Chloramphenicol Diminish Neutrophil Extracellular Traps (NETs) release. Int J Mol Sci. 2017;18(12).
111.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319–30.PubMedCrossRef
112.
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994–2004.PubMedCrossRef
113.
Warfarin Antiplatelet Vascular Evaluation, Trial I, Anand S, Yusuf S, Xie C, Pogue J, Eikelboom J, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–27.CrossRef
114.
Ten Cate H, Guzik TJ, Eikelboom J, Spronk HMH. Pleiotropic actions of factor xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovasc Res. 2021;117(9):2030–44.PubMedCrossRef
115.
Moll F, Baumgartner I, Jaff M, Nwachuku C, Tangelder M, Ansel G, et al. Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular treatment of patients with peripheral artery disease: results of the ePAD Trial. J Endovasc Ther. 2018;25(2):158–68.PubMedCrossRef
116.
Biagioni RB, Lopes RD, Agati LB, Sacilotto R, Wolosker N, Sobreira ML, et al. Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial. Am Heart J. 2020;227:100–6.PubMedCrossRef
117.
Vinholt PJ, Nielsen C, Soderstrom AC, Brandes A, Nybo M. Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. J Thromb Thrombolysis. 2017;44(2):216–22.PubMedCrossRef
118.
Darwood R, Berridge DC, Kessel DO, Robertson I, Forster R. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev. 2018;8(8):CD002784.PubMed
119.
Morrow GB, Mutch NJ. Past, Present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost. 2023;49(3):305–13.PubMedCrossRef
120.
Brogren H, Wallmark K, Deinum J, Karlsson L, Jern S. Platelets retain high levels of active plasminogen activator inhibitor 1. PLoS ONE. 2011;6(11):e26762.PubMedPubMedCentralCrossRef
121.
Festa A, D’Agostino R Jr., Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131–7.PubMedCrossRef
122.
Bastard JP, Pieroni L. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. Biomed Pharmacother. 1999;53(10):455–61.PubMedCrossRef
123.
Heiman M, Gupta S, Lewandowska M, Shapiro AD. Complete Plasminogen Activator Inhibitor 1 Deficiency. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, editors. GeneReviews((R)). Seattle (WA)1993.
124.
Sillen M, Declerck PJ. Targeting PAI-1 in Cardiovascular Disease: structural insights into PAI-1 functionality and inhibition. Front Cardiovasc Med. 2020;7:622473.PubMedPubMedCentralCrossRef
125.
Abdul S, Leebeek FW, Rijken DC, Uitte de Willige S. Natural heterogeneity of alpha2-antiplasmin: functional and clinical consequences. Blood. 2016;127(5):538–45.PubMedCrossRef
126.
Singh S, Saleem S, Reed GL. Alpha2-Antiplasmin: the Devil you don’t know in Cerebrovascular and Cardiovascular Disease. Front Cardiovasc Med. 2020;7:608899.PubMedPubMedCentralCrossRef
127.
Muszbek L, Bereczky Z, Bagoly Z, Shemirani AH, Katona E. Factor XIII and atherothrombotic diseases. Semin Thromb Hemost. 2010;36(1):18–33.PubMedCrossRef
128.
Shemirani AH, Szomjak E, Csiki Z, Katona E, Bereczky Z, Muszbek L. Elevated factor XIII level and the risk of peripheral artery disease. Haematologica. 2008;93(9):1430–2.PubMedCrossRef
129.
Soendergaard C, Kvist PH, Seidelin JB, Nielsen OH. Tissue-regenerating functions of coagulation factor XIII. J Thromb Haemost. 2013;11(5):806–16.PubMedCrossRef
130.
Schmitz T, Bauml CA, Imhof D. Inhibitors of blood coagulation factor XIII. Anal Biochem. 2020;605:113708.PubMedCrossRef
131.
132.
Violi F, Calvieri C, Ferro D, Pignatelli P. Statins as antithrombotic drugs. Circulation. 2013;127(2):251–7.PubMedCrossRef
133.
Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol. 2013;62(6):505–12.PubMedCrossRef
Metadata
Title
Diabetes- versus smoking-related thrombo-inflammation in peripheral artery disease
Authors
T. Alnima
R. I. Meijer
H. M.H. Spronk
M. Warlé
H. ten Cate
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-023-01990-6

Other articles of this Issue 1/2023

Cardiovascular Diabetology 1/2023 Go to the issue

Review

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Research

Glycemic control, HbA1c variability, and major cardiovascular adverse outcomes in type 2 diabetes patients with elevated cardiovascular risk: insights from the ACCORD study

Research

Dysregulated Rbfox2 produces aberrant splicing of CaV1.2 calcium channel in diabetes-induced cardiac hypertrophy

Research

Acid sphingomyelinase promotes diabetic cardiomyopathy via NADPH oxidase 4 mediated apoptosis

Research

Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study

Correction

Correction: Comparison of 2‑year mortality according to obesity in stabilized patients with type 2 diabetes mellitus after acute myocardial infarction: results from the DIAMOND prospective cohort registry
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits